Don't give up on finding alternatives for your depression

Consider a research study evaluating a new option for people with depression who have tried 2 or more medications without sufficient improvement.

About the Study

The Cleo Study is evaluating an oral study medication, an oral esketamine tablet, to see if it may reduce symptoms of depression. If you have tried at least 2 medications for your depression and have not seen sufficient improvement, the Cleo Study may be an option. If you qualify for the study, you would continue taking your current depression medication along with the oral study medication.

Who can participate in the study?

You may be able to participate in the Cleo Study if you:*

  • Are 18 to 65 years old
  • Have been diagnosed with depression, also known as major depressive disorder
  • Have tried at least 2 medications for depression without sufficient improvement
  • Have had depression symptoms for at least 12 weeks
  • Are on a stable dose of antidepressant medication for at least 4-5 weeks

*Other criteria will apply.

Why Participate

If you qualify and enroll, you will receive:

  • All study-related care, including assigned study medication, at no cost
  • Close monitoring of your depression by an experienced study team
  • The opportunity to advance medical science for depression that does not respond adequately to other medications

Your participation is voluntary, and you may choose to withdraw from the study at any time.

About Depression

Major Depressive Disorder (MDD), also referred to as clinical depression, is a medical condition where feelings of sadness or other symptoms last longer than 2 weeks at a time and interfere with your daily life.1


People living with depression often experience:

  • A loss of interest in activities
  • Changes in sleep, appetite, energy level, and concentration
  • Difficulty keeping up with their daily routine
  • Feelings of isolation


Up to one-third of individuals diagnosed with depression do not adequately respond to existing treatments for their symptoms, so there is a need for new therapies.2 This inadequate response can be referred to as treatment-resistant depression, generally defined as having tried at least 2 medications for depression with little or no improvement in symptoms.


  1. Depression. Overview. National Institute of Mental Health. Accessed September 21, 2020.
  2. Rush AJ., Trivedi MH., Wisniewski SR., et al Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.

Frequently Asked Questions

This section will help answer some of the important questions you may have.


About the Cleo Study

  • Why is this clinical research study being conducted?

  • What can I expect if I participate in the Cleo Study?

  • How do I decide if this clinical research study is right for me?

  • Is there a placebo in this study?

  • Can I withdraw from the study after I have started?

  • Does my doctor need to give me permission to participate?

  • Who can I contact with more questions?

  • Will my personal information be kept private?

  • Will I be paid for taking part or reimbursed for travel?

  • How many people will participate?

  • Who is the study sponsor?

About Clinical Research

  • What is a clinical research study?

  • Who oversees clinical research studies?

This website uses cookies. A “cookie” is a file sent to your computer when you access a website. By using this site, you agree to the use of cookies on your device for tracking and analytics as described in the Cookie section of our Privacy Policy.

Are you sure you want to close?